psychiatric disorders that are the usual target of these agents, replicating prior observations.64,65 The potential therapeutic utility of anti-inflammatory and blood glucose lowering medications was also suggested by our analyses, in addition to an anti-Parkinson medication known to interact with dopaminergic activity (i.e., biperiden) and one that acts both as an antagonist of acetylcholinesterase and an agonist of nicotinic receptors (i.e., galantamine), as shown in recent independent studies.65,66 Although, to date, no repurposed drugs have been developed for treating SUDs based on GWAS data, this is an important potential path forward, particularly for SUDs, where few effective pharmacotherapies are available.
